From the Lab to the Enterprise: How B. Parthasaradhi Reddy Built Hetero

 

BIZ MASALA  •  PEOPLE, BUSINESS & INDIA

THE FOUNDER'S JOURNEY

Dr. B. Parthasaradhi Reddy, founder and chairman of Hetero Group. Photo supplied.

From the Lab to the Enterprise: How B. Parthasaradhi Reddy Built Hetero

By Murthy ASR | Biz Masala

A scientist’s R&D instincts became the foundation of a privately held pharmaceutical group with a global footprint.

THE STORY AT A GLANCE

Topic

Snapshot

Founded

Hetero was founded in 1993 by Dr. B. Parthasaradhi Reddy.

Scientific background

Ph.D. and M.Sc. in chemistry from Osmania University, Hyderabad, according to Hetero.

Early career

Reddy said he worked at Dr. Reddy’s Laboratories for 13 years before founding Hetero.

Core strengths

APIs, generic medicines, research, manufacturing and international supply.

Public role

Reddy is a Rajya Sabha member associated with the BRS.

Valuation caution

A ₹50,000-crore group enterprise value is not treated as verified in this article.

The scientist who saw a bigger possibility

Dr. B. Parthasaradhi Reddy’s story begins in a laboratory, not a boardroom. Before founding Hetero in 1993, he spent 13 years at Dr. Reddy’s Laboratories. In a 2012 interview, he described himself as a scientist by background and said research and development shaped Hetero’s early priorities. The first years, he recalled, were heavily focused on R&D.

That instinct became part of Hetero’s identity. In pharmaceuticals, a promising idea is only the beginning: chemistry has to work consistently, quality must hold from batch to batch, and production has to scale without compromising standards. Reddy’s scientific background gave the young company a way to think about those challenges from the inside.

Building Hetero around science

Hetero’s current portfolio spans active pharmaceutical ingredients (APIs)—the substances that give medicines their therapeutic effect—and finished formulations. The company’s own profile describes strengths in research, manufacturing and marketing, while its R&D page highlights work on complex APIs, generics, biosimilars and drug-delivery technologies.

The company also built a significant position in antiretroviral medicines. Hetero says its work on affordable APIs helped expand access to HIV/AIDS treatments. That is a commercially important niche as well as a public-health contribution: reliable supply and competitive production costs matter when medicines must reach large populations across multiple countries.

Hetero’s pharmaceutical facility. Photo supplied.

From a small lab to a global footprint

In the 2012 PharmaBoardroom interview, Reddy recalled that Hetero began in a small laboratory and had grown into a business with thousands of employees and international manufacturing capabilities. Those historical figures should not be read as current headcount or capacity; they show the scale of the transformation he described at the time.

One memory from Hetero’s early years has stayed with me. During my interactions with Dr. B. Parthasaradhi Reddy in 1998–99, he told me that some of the key people who joined him at the beginning had been promised cars—and that he fulfilled the promise within the first year. I did not independently witness the handover; this is how the founder recounted it to me. The detail matters because it brings the story down from corporate scale to the people who took a chance on a young enterprise. Trust, in a growing company, is built not only through strategy and capital, but also through commitments remembered and honoured.

A restaurant encounter that stayed with me

Another memory gave me a glimpse of Dr. Reddy away from the world of business. I had gone with my family for dinner at Shanbagh in Panjagutta, Hyderabad, a restaurant I regarded as an everyday, middle-class place to eat. I was surprised to see Dr. B. Parthasaradhi Reddy arrive there with his wife and daughter, Sindhu. The encounter stayed with me because it challenged the assumptions people can make about how a successful industrialist chooses to live. It was a small, ordinary moment—not proof of a person's entire character, but a personal impression of someone comfortable in an unpretentious setting.

I have also understood him to be generous, including through donations associated with religious and community causes such as the Shirdi temple. Specific donation amounts and details should be included only where they can be supported by reliable public records. Taken together with my own recollections of meeting him, these details add a personal dimension to the portrait—but the distinction between firsthand memory and independently documented philanthropy should remain clear.

Over time, Hetero developed capabilities across both active pharmaceutical ingredients (APIs) and finished medicines. Bringing more of that work under one roof can help a manufacturer manage cost, quality and supply. It also demands sustained investment in people, plants, regulatory systems and execution.

Hetero office building. Photo supplied.

Reading the numbers carefully

Hetero is a group with multiple legal entities. For that reason, a single subsidiary’s financial statements should not be presented as the consolidated performance of the whole group. The chart below shows reported FY2024–25 figures attributed to Hetero Labs Limited in a third-party company-information compilation; they are company-level figures, not a group-wide valuation.

Source: The Company Check compilation for Hetero Labs Limited, FY2024–25. Company-level figures only.

A frequently repeated estimate values Hetero at around ₹50,000 crore, but that figure should not be treated as a confirmed valuation without a credible valuation report or disclosed transaction. Enterprise value, equity value, revenue and a promoter’s personal wealth are different measures—and should not be used interchangeably.

Business, public life and responsibility

Reddy also serves in the Rajya Sabha and is associated with the Bharat Rashtra Samithi (BRS). That public role forms another strand of his profile, separate from the business itself. The distinction matters: political responsibilities and a company’s commercial performance should be assessed on their own evidence.

A family’s move into healthcare

Prime Minister Narendra Modi at the Sindhu Hospitals inauguration on 10 May 2026. Photo supplied.

Sindhu Hospitals in Hyderabad adds a healthcare-delivery dimension to the family’s story. Prime Minister Narendra Modi inaugurated the hospital on 10 May 2026, according to official reporting. Its presence broadens the family’s footprint beyond pharmaceutical manufacturing into the delivery of healthcare. The two activities are connected by a broad public-health context, but they are different businesses with different operating demands.

The idea that still defines the enterprise

Reddy’s journey offers a reminder that scientific knowledge becomes a business advantage only when it is matched by manufacturing discipline, dependable quality, regulatory expertise and the ability to reach markets. In pharmaceuticals, reputation is earned repeatedly—one product, one batch and one market at a time.

THE BIZ MASALA PERSPECTIVE

Hetero’s story is about more than scale. Its R&D-first beginnings helped establish a technical base for a business that grew across products and markets. The enduring test is whether that scientific discipline continues to shape the company as it matures.

Sources and reporting notes

·       Hetero official leadership profile: https://www.hetero.com/leadership

·       Hetero official R&D overview: https://www.hetero.com/research-development

·       Background source: PharmaBoardroom interview with Dr. Bandi Parthasaradhi Reddy, 25 July 2012: https://pharmaboardroom.com/interviews/interview-with-dr-bandi-parthasaradhi-reddy-hetero-drugs-limited/

·       The Company Check, Hetero Labs Limited company profile and FY2024–25 figures: https://www.thecompanycheck.com/company/hetero-labs-limited/U24110TG1989PLC009723

·       PIB, Sindhu Hospitals inauguration, 10 May 2026: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2259572&lang=1&reg=3

Editorial note: This profile distinguishes company-level financial data from group-wide performance. The ₹50,000-crore valuation estimate and the precise claim that Hetero began with fewer than 10 people are not presented as verified facts. The anecdote about early colleagues being promised cars and receiving them within the first year is included as an unverified recollection and requires first-hand confirmation before publication.

 

BIZ MASALA  •  BUSINESS. MARKETS. PEOPLE. INSIGHT.

Comments

Post a Comment

Popular posts from this blog

WHO TESTS THE MEDICINES INDIA MAKES?

Image
  BIZ MASALA SIGNATURE STORY Inside the business of pharmaceutical testing laboratories — the money, the market and the science behind a medicine’s quality By Murthy ASR   |   18 October 2026 Illustrative editorial image: pharmaceutical analytical testing laboratory. A medicine may be manufactured on a modern production line, packed in a clean facility and shipped across the world. But before a batch can be trusted, its quality has to be demonstrated. Behind that assurance is a less visible industry: laboratories that test ingredients, finished formulations, impurities, stability and, where relevant, biological characteristics. For India, this is more than a technical service. The country’s pharmaceutical manufacturers supply domestic patients and regulated markets overseas. Their products must meet specifications, documentation requirements and regulatory expectations that vary by medicine and destination. Testing laboratories help generate the evidence on ...
Read more

The Poet-Builder of Indian Infrastructure

Image
  BIZ MASALA SPECIAL FEATURE   |   CORPORATE RETROSPECTIVE The Poet-Builder of Indian Infrastructure A retrospective on Dr. A.V.S. Raju — the entrepreneur who built a construction institution and pursued an extraordinary literary life Dr. A.V.S. Raju. Portrait supplied for this Biz Masala feature. A builder whose second life was on the page India’s infrastructure story is usually told through concrete, contracts, highways, dams and balance sheets. Dr. Alluri Venkata Satyanarayana Raju—known as A.V.S. Raju—complicated that familiar portrait. He helped build Nagarjuna Construction Company into a national engineering and construction business, while devoting an extraordinary amount of time to Telugu poetry and devotional writing. His death in Hyderabad on 13 October 2026, aged 89, closes a chapter in the story of a founder whose interests extended well beyond the construction site. Born on 18 April 1937 in Antarvedipalem, in the erstwhile East Godavari dist...
Read more